1. Home
  2. TVRD vs SJT Comparison

TVRD vs SJT Comparison

Compare TVRD & SJT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • SJT
  • Stock Information
  • Founded
  • TVRD 2017
  • SJT 1980
  • Country
  • TVRD United States
  • SJT United States
  • Employees
  • TVRD N/A
  • SJT N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • SJT Oil & Gas Production
  • Sector
  • TVRD Health Care
  • SJT Energy
  • Exchange
  • TVRD Nasdaq
  • SJT Nasdaq
  • Market Cap
  • TVRD 246.5M
  • SJT 269.4M
  • IPO Year
  • TVRD N/A
  • SJT N/A
  • Fundamental
  • Price
  • TVRD $6.73
  • SJT $5.88
  • Analyst Decision
  • TVRD Buy
  • SJT
  • Analyst Count
  • TVRD 7
  • SJT 0
  • Target Price
  • TVRD $51.67
  • SJT N/A
  • AVG Volume (30 Days)
  • TVRD 467.6K
  • SJT 233.3K
  • Earning Date
  • TVRD 11-21-2025
  • SJT 11-13-2025
  • Dividend Yield
  • TVRD N/A
  • SJT N/A
  • EPS Growth
  • TVRD N/A
  • SJT N/A
  • EPS
  • TVRD N/A
  • SJT N/A
  • Revenue
  • TVRD N/A
  • SJT $42,635.00
  • Revenue This Year
  • TVRD N/A
  • SJT N/A
  • Revenue Next Year
  • TVRD N/A
  • SJT N/A
  • P/E Ratio
  • TVRD N/A
  • SJT N/A
  • Revenue Growth
  • TVRD N/A
  • SJT N/A
  • 52 Week Low
  • TVRD $5.65
  • SJT $3.66
  • 52 Week High
  • TVRD $43.65
  • SJT $7.22
  • Technical
  • Relative Strength Index (RSI)
  • TVRD 20.91
  • SJT 44.99
  • Support Level
  • TVRD $5.65
  • SJT $5.76
  • Resistance Level
  • TVRD $7.11
  • SJT $6.33
  • Average True Range (ATR)
  • TVRD 2.47
  • SJT 0.24
  • MACD
  • TVRD -4.16
  • SJT -0.04
  • Stochastic Oscillator
  • TVRD 3.26
  • SJT 13.52

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About SJT San Juan Basin Royalty Trust

San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.

Share on Social Networks: